Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Chembio Diagnostics awarded $3.2M contract from CDC » 08:08
09/06/22
09/06
08:08
09/06/22
08:08
CEMI

Chembio Diagnostics

/

+

Chembio Diagnostics…

Chembio Diagnostics announced it was awarded a $3.2M contract from the Centers for Disease Control and Prevention, or CDC, for the development and clinical validation of a rapid point-of-care, or POC, diagnostic test for syphilis. Chembio will undertake to develop a syphilis test and confirm assay based on its Dual Path Platform (DPP) technology and proprietary DPP Micro Reader II. The assay will be intended to simultaneously and separately detect treponemal and nontreponemal IgM and IgG antibodies. The test should require only 10 microL of fingerstick blood, serum, or plasma and produce results in under 20 minutes. Serologic tests are currently available in clinical laboratories for the detection of active syphilis, which require shipping samples to perform tests of moderate or high complexity. There is no rapid point-of-care test currently available to accomplish both screening and confirmation of active syphilis. The development of such a test should allow for rapid diagnosis of an active infection and timely patient treatment, thus reducing the overall burden of syphilis in the U.S.

ShowHide Related Items >><<
CEMI Chembio Diagnostics
/

+

CEMI Chembio Diagnostics
/

+

12/29/21 Benchmark
Chembio news does not impact near-term estimates, says Benchmark
Over a month ago
Hot Stocks
Chembio Diagnostics evaluates monkeypox rapid POC test development » 08:05
08/16/22
08/16
08:05
08/16/22
08:05
CEMI

Chembio Diagnostics

/

+

Chembio Diagnostics…

Chembio Diagnostics announced it is evaluating the potential to develop a monkeypox rapid point-of-care test. Chembio is exploring the technical requirements for test development leveraging its multiple technology platforms, DPP, SURE CHECK, and STAT PAK, along with funding partners and the broader market opportunity. Currently, the FDA has cleared one test to detect monkeypox, offered through the U.S. Centers for Disease Control and Prevention as a lab developed test. The test utilizes a swab sample from a monkeypox lesion, creating the need for earlier detection to limit the spread of the disease and expedite treatment.

ShowHide Related Items >><<
CEMI Chembio Diagnostics
/

+

CEMI Chembio Diagnostics
/

+

12/29/21 Benchmark
Chembio news does not impact near-term estimates, says Benchmark
CEMI Chembio Diagnostics
/

+

Over a quarter ago
Hot Stocks
Chembio announces expansion of direct-to-consumer commercial channel » 08:03
06/15/22
06/15
08:03
06/15/22
08:03
CEMI

Chembio Diagnostics

/

+

Chembio Diagnostics…

Chembio Diagnostics announced the launch of its direct-to-consumer commercial channel for the third-party SCoV-2 Ag Detect Self-Test in the U.S. market. In addition, Chembio is expanding distribution of its SURE CHECK HIV Self-Test to consumers in Brazil and the United Kingdom by broadening the test kit's existing Over-the-Counter, OTC, availability in national pharmacy chains. "We are excited to expand patient access to rapid, accurate and easy to use at home diagnostics across the United States, Brazil and the United Kingdom," said Richard Eberly, Chembio's Chief Executive Officer and President. "We are now offering the SCoV-2 Ag Detect Self-Test via our distribution network and directly through Chembio in the US. In addition, we are now offering our SURE CHECK HIV Self-Test through e-commerce platforms in the UK and Brazil. This commercial expansion increases our addressable market and is intended to enable deeper penetration of the market as at home testing volumes continue to grow. This initiative directly aligns with our goal to focus on higher margin business in growing markets under our Global Competitiveness Program."

ShowHide Related Items >><<
CEMI Chembio Diagnostics
/

+

CEMI Chembio Diagnostics
/

+

12/29/21 Benchmark
Chembio news does not impact near-term estimates, says Benchmark
07/22/21 Benchmark
Chembio's Ethiopia order factored in estimates, says Benchmark
07/21/21 Colliers
Colliers downgrades Chembio Diagnostics, says current price 'too aggressive'
07/21/21 Colliers
Chembio Diagnostics downgraded to Neutral from Buy at Colliers
CEMI Chembio Diagnostics
/

+

CEMI Chembio Diagnostics
/

+

Conference/Events
Chembio Diagnostics participates in a conference call with Benchmark » 04:55
05/25/22
05/25
04:55
05/25/22
04:55
CEMI

Chembio Diagnostics

/

+

Analyst Jackson holds a…

Analyst Jackson holds a conference call with CEO Eberly and CFO Steenvoorden on May 25 hosted by Benchmark.

ShowHide Related Items >><<
CEMI Chembio Diagnostics
/

+

CEMI Chembio Diagnostics
/

+

12/29/21 Benchmark
Chembio news does not impact near-term estimates, says Benchmark
07/22/21 Benchmark
Chembio's Ethiopia order factored in estimates, says Benchmark
07/21/21 Colliers
Colliers downgrades Chembio Diagnostics, says current price 'too aggressive'
07/21/21 Colliers
Chembio Diagnostics downgraded to Neutral from Buy at Colliers
CEMI Chembio Diagnostics
/

+

CEMI Chembio Diagnostics
/

+

CEMI Chembio Diagnostics
/

+

Hot Stocks
Chembio Diagnostics enters manufacturing agreement with Reszon » 08:11
05/17/22
05/17
08:11
05/17/22
08:11
CEMI

Chembio Diagnostics

/

+

Chembio Diagnostics…

Chembio Diagnostics announced it has entered into a manufacturing agreement with Reszon Diagnostics International to produce Chembio's HIV 1/2 STAT-PAK Assay products in the Chembio Diagnostics Malaysia, CDM, facility. CDM had previously suspended operations in May 2020. This new manufacturing arrangement will leverage CDM's product and facility qualification by the World Health Organization Prequalification Program and ISO 13485 certification. The relationship will also combine Chembio's manufacturing abilities with Reszon's resources and manufacturing strengths in the diagnostics space. Operations are planned to commence in the third quarter of 2022 dependent on reaching certain quality, production and other targets. "We are excited to be working with Reszon, a leader in Malaysian diagnostics test kits, to optimize our global manufacturing by leveraging our Malaysian resources. This represents a major milestone in our Global Competitiveness Program to improve profitability," said Richard Eberly, Chembio's Chief Executive Officer and President. "We believe this new relationship will increase our capacity to supply new markets, bolster our competitiveness and strengthen our position in rapid point-of-care testing. We look forward to exploring commercial opportunities in Malaysia and other high-growth markets."

ShowHide Related Items >><<
CEMI Chembio Diagnostics
/

+

CEMI Chembio Diagnostics
/

+

12/29/21 Benchmark
Chembio news does not impact near-term estimates, says Benchmark
07/22/21 Benchmark
Chembio's Ethiopia order factored in estimates, says Benchmark
07/21/21 Colliers
Colliers downgrades Chembio Diagnostics, says current price 'too aggressive'
07/21/21 Colliers
Chembio Diagnostics downgraded to Neutral from Buy at Colliers
CEMI Chembio Diagnostics
/

+

CEMI Chembio Diagnostics
/

+

CEMI Chembio Diagnostics
/

+

Conference/Events
Chembio Diagnostics participates in a conference call with Benchmark » 15:40
05/16/22
05/16
15:40
05/16/22
15:40
CEMI

Chembio Diagnostics

/

+

Analyst Jackson holds a…

Analyst Jackson holds a conference call with CEO Eberly and CFO Steenvoorden on May 25 hosted by Benchmark.

ShowHide Related Items >><<
CEMI Chembio Diagnostics
/

+

CEMI Chembio Diagnostics
/

+

12/29/21 Benchmark
Chembio news does not impact near-term estimates, says Benchmark
07/22/21 Benchmark
Chembio's Ethiopia order factored in estimates, says Benchmark
07/21/21 Colliers
Colliers downgrades Chembio Diagnostics, says current price 'too aggressive'
07/21/21 Colliers
Chembio Diagnostics downgraded to Neutral from Buy at Colliers
CEMI Chembio Diagnostics
/

+

CEMI Chembio Diagnostics
/

+

CEMI Chembio Diagnostics
/

+

Earnings
Chembio Diagnostics reports Q4 EPS (47c), two estimates (20c) » 16:47
03/03/22
03/03
16:47
03/03/22
16:47
CEMI

Chembio Diagnostics

/

+

Reports Q4 revenue…

Reports Q4 revenue $20.57M, two estimates $13.55M. "In the fourth quarter, record quarterly revenue was driven by execution of the largest purchase order in company history, received from Bio-Manguinhos for DPP SARS-CoV-2 Antigen Tests in Brazil, while navigating the tight labor market and global supply chain issues for certain test components to ramp production. Chembio also finished the year with record annual revenue," said Richard Eberly, Chembio's president and CEO. "We are confident our investments in developing products in high value growing markets and registering existing products in additional geographies can drive sustained growth over the long-term. We are optimistic about our ability to improve profitability through continued product revenue growth and reduction of our cost infrastructure beginning in 2022."

ShowHide Related Items >><<
CEMI Chembio Diagnostics
/

+

CEMI Chembio Diagnostics
/

+

12/29/21 Benchmark
Chembio news does not impact near-term estimates, says Benchmark
07/22/21 Benchmark
Chembio's Ethiopia order factored in estimates, says Benchmark
07/21/21 Colliers
Colliers downgrades Chembio Diagnostics, says current price 'too aggressive'
07/21/21 Colliers
Chembio Diagnostics downgraded to Neutral from Buy at Colliers
CEMI Chembio Diagnostics
/

+

CEMI Chembio Diagnostics
/

+

Hot Stocks
Chembio Diagnostics appoints Larry Steenvoorden as CFO » 16:09
01/05/22
01/05
16:09
01/05/22
16:09
CEMI

Chembio Diagnostics

$1.13 /

-0.045 (-3.85%)

Chembio Diagnostics…

Chembio Diagnostics announced the appointment of Larry Steenvoorden as CFO effective immediately. Steenvoorden served as a senior director at Accordion Partners, providing CFO advisory services to private equity backed companies for the past four years.

ShowHide Related Items >><<
CEMI Chembio Diagnostics
$1.13 /

-0.045 (-3.85%)

CEMI Chembio Diagnostics
$1.13 /

-0.045 (-3.85%)

12/29/21 Benchmark
Chembio news does not impact near-term estimates, says Benchmark
07/22/21 Benchmark
Chembio's Ethiopia order factored in estimates, says Benchmark
07/21/21 Colliers
Colliers downgrades Chembio Diagnostics, says current price 'too aggressive'
07/21/21 Colliers
Chembio Diagnostics downgraded to Neutral from Buy at Colliers
CEMI Chembio Diagnostics
$1.13 /

-0.045 (-3.85%)

CEMI Chembio Diagnostics
$1.13 /

-0.045 (-3.85%)

CEMI Chembio Diagnostics
$1.13 /

-0.045 (-3.85%)

Recommendations
Chembio news does not impact near-term estimates, says Benchmark » 10:58
12/29/21
12/29
10:58
12/29/21
10:58
CEMI

Chembio Diagnostics

$1.24 /

-0.32 (-20.51%)

Benchmark analyst Bruce…

Benchmark analyst Bruce Jackson keeps a Hold rating on Chembio Diagnostics after the company announced that the FDA will require prospectively collected samples of influenza A and influenza B to support the Emergency Use Authorization application for its DPP multiplex Respiratory Antigen Panel for the simultaneous detection of influenza A, influenza B and COVID-19. The analyst says that while negative for the stock, the news does not impact his estimates for the next few quarters as they are driven by large orders from Brazil and Africa. Jackson adds he "could get more constructive on the shares only if the company is able to sustain a higher rate of core revenue (and overhead absorption) after it chews through the Bio Manguinhos order."

ShowHide Related Items >><<
CEMI Chembio Diagnostics
$1.24 /

-0.32 (-20.51%)

CEMI Chembio Diagnostics
$1.24 /

-0.32 (-20.51%)

07/22/21 Benchmark
Chembio's Ethiopia order factored in estimates, says Benchmark
07/21/21 Colliers
Colliers downgrades Chembio Diagnostics, says current price 'too aggressive'
07/21/21 Colliers
Chembio Diagnostics downgraded to Neutral from Buy at Colliers
CEMI Chembio Diagnostics
$1.24 /

-0.32 (-20.51%)

CEMI Chembio Diagnostics
$1.24 /

-0.32 (-20.51%)

CEMI Chembio Diagnostics
$1.24 /

-0.32 (-20.51%)

On The Fly
Fly Intel: Pre-market Movers » 08:52
12/29/21
12/29
08:52
12/29/21
08:52
TSLA

Tesla

$1,088.39 /

-5.36 (-0.49%)

, VSCO

Victoria's Secret

$48.55 /

-0.01 (-0.02%)

, FNA

Paragon 28

$16.47 /

-0.205 (-1.23%)

, CANF

Can-Fite BioPharma

$1.26 /

-0.04 (-3.08%)

, FCEL

FuelCell

$5.87 /

-0.44 (-6.97%)

, CALM

Cal-Maine Foods

$38.28 /

+1.4 (+3.80%)

, CEMI

Chembio Diagnostics

$1.56 /

-0.12 (-7.14%)

, OSH

Oak Street Health

$33.90 /

-1.26 (-3.58%)

, AUVI

Applied UV

$3.55 /

-0.58 (-14.06%)

, MFIN

Medallion Financial

$8.45 /

-0.07 (-0.82%)

Check out this morning's…

ShowHide Related Items >><<
VSCO Victoria's Secret
$48.55 /

-0.01 (-0.02%)

TSLA Tesla
$1,088.39 /

-5.36 (-0.49%)

OSH Oak Street Health
$33.90 /

-1.26 (-3.58%)

MFIN Medallion Financial
$8.45 /

-0.07 (-0.82%)

FNA Paragon 28
$16.47 /

-0.205 (-1.23%)

FCEL FuelCell
$5.87 /

-0.44 (-6.97%)

CEMI Chembio Diagnostics
$1.56 /

-0.12 (-7.14%)

CANF Can-Fite BioPharma
$1.26 /

-0.04 (-3.08%)

CALM Cal-Maine Foods
$38.28 /

+1.4 (+3.80%)

AUVI Applied UV
$3.55 /

-0.58 (-14.06%)

TSLA Tesla
$1,088.39 /

-5.36 (-0.49%)

12/28/21 BofA
BofA sees December U.S. light vehicle sales down 20%
12/28/21 Argus
Tesla price target raised to $1,313 from $1,010 at Argus
12/28/21 Wedbush
Tesla in 'clear position of strength' heading into 2022, says Wedbush
12/23/21 Credit Suisse
Credit Suisse expects Tesla Q4 deliveries of 290k, volume dictated by supply
VSCO Victoria's Secret
$48.55 /

-0.01 (-0.02%)

12/27/21 Morgan Stanley
Victoria's Secret price target lowered to $54 from $69 at Morgan Stanley
11/30/21 Jefferies
Victoria's Secret assumed with a Buy at Jefferies
11/19/21 Morgan Stanley
Victoria's Secret price target lowered to $69 from $76 at Morgan Stanley
11/19/21 B. Riley
Victoria's Secret price target lowered to $77 from $87 at B. Riley
FNA Paragon 28
$16.47 /

-0.205 (-1.23%)

11/22/21 Piper Sandler
Paragon 28 a 'name to own' after strong first public report, says Piper Sandler
11/09/21 Canaccord
Canaccord starts foot & ankle share taker Paragon 28 with a Buy
11/09/21 Needham
Paragon 28 initiated with a Buy at Needham
11/09/21 Canaccord
Paragon 28 initiated with a Buy at Canaccord
CANF Can-Fite BioPharma
$1.26 /

-0.04 (-3.08%)

11/30/21 Alliance Global Partners
Can-Fite price target lowered to $8.25 from $9 at Alliance Global Partners
06/15/21 Alliance Global Partners
Can-Fite BioPharma initiated with a Buy at Alliance Global Partners
FCEL FuelCell
$5.87 /

-0.44 (-6.97%)

09/15/21 B. Riley
FuelCell price target lowered to $8 from $10 at B. Riley
06/11/21 B. Riley
FuelCell price target lowered to $10 from $11 at B. Riley
06/11/21 Canaccord
FuelCell price target lowered to $9.00 from $13.50 at Canaccord
04/19/21 Wells Fargo
Wells Fargo starts FuelCell at Underweight, sees commercialization behind peers
CALM Cal-Maine Foods
$38.28 /

+1.4 (+3.80%)

05/26/21 BofA
Cal-Maine Foods downgraded to Underperform from Buy at BofA
12/30/20 Stephens
Cal-Maine Foods price target lowered to $47 from $55 at Stephens
CEMI Chembio Diagnostics
$1.56 /

-0.12 (-7.14%)

07/22/21 Benchmark
Chembio's Ethiopia order factored in estimates, says Benchmark
07/21/21 Colliers
Colliers downgrades Chembio Diagnostics, says current price 'too aggressive'
07/21/21 Colliers
Chembio Diagnostics downgraded to Neutral from Buy at Colliers
OSH Oak Street Health
$33.90 /

-1.26 (-3.58%)

12/17/21 Morgan Stanley
Oak Street Health downgraded to Equal Weight at Morgan Stanley
12/16/21 Morgan Stanley
Oak Street Health downgraded to Equal Weight from Overweight at Morgan Stanley
11/12/21 Morgan Stanley
Oak Street Health price target lowered to $44 from $60 at Morgan Stanley
11/10/21 Piper Sandler
Piper Sandler 'defending' Oak Street Health after 21% selloff
AUVI Applied UV
$3.55 /

-0.58 (-14.06%)

MFIN Medallion Financial
$8.45 /

-0.07 (-0.82%)

05/06/21 B. Riley
Medallion Financial price target raised to $12 from $11 at B. Riley
04/07/21 B. Riley
Medallion Financial price target raised to $11 from $10 at B. Riley
02/19/21 B. Riley
Medallion Financial price target raised to $10 from $8 at B. Riley Securities
VSCO Victoria's Secret
$48.55 /

-0.01 (-0.02%)

TSLA Tesla
$1,088.39 /

-5.36 (-0.49%)

OSH Oak Street Health
$33.90 /

-1.26 (-3.58%)

MFIN Medallion Financial
$8.45 /

-0.07 (-0.82%)

FNA Paragon 28
$16.47 /

-0.205 (-1.23%)

FCEL FuelCell
$5.87 /

-0.44 (-6.97%)

CEMI Chembio Diagnostics
$1.56 /

-0.12 (-7.14%)

CANF Can-Fite BioPharma
$1.26 /

-0.04 (-3.08%)

CALM Cal-Maine Foods
$38.28 /

+1.4 (+3.80%)

  • 15
    Oct
  • 27
    May
  • 11
    Feb
TSLA Tesla
$1,088.39 /

-5.36 (-0.49%)

VSCO Victoria's Secret
$48.55 /

-0.01 (-0.02%)

TSLA Tesla
$1,088.39 /

-5.36 (-0.49%)

OSH Oak Street Health
$33.90 /

-1.26 (-3.58%)

MFIN Medallion Financial
$8.45 /

-0.07 (-0.82%)

FNA Paragon 28
$16.47 /

-0.205 (-1.23%)

FCEL FuelCell
$5.87 /

-0.44 (-6.97%)

CEMI Chembio Diagnostics
$1.56 /

-0.12 (-7.14%)

CANF Can-Fite BioPharma
$1.26 /

-0.04 (-3.08%)

CALM Cal-Maine Foods
$38.28 /

+1.4 (+3.80%)

AUVI Applied UV
$3.55 /

-0.58 (-14.06%)

VSCO Victoria's Secret
$48.55 /

-0.01 (-0.02%)

TSLA Tesla
$1,088.39 /

-5.36 (-0.49%)

FCEL FuelCell
$5.87 /

-0.44 (-6.97%)

CEMI Chembio Diagnostics
$1.56 /

-0.12 (-7.14%)

CALM Cal-Maine Foods
$38.28 /

+1.4 (+3.80%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.